Essential Thrombocythemia

Common Name(s)

Essential Thrombocythemia

Essential thrombocythemia belongs to a group of conditions called myeloproliferative disorders. Myeloproliferative disorders cause platelets, white blood cells and red blood cells to grow abnormally in the bone marrow (the soft tissue inside the hollow part of bones that helps form blood cells). In essential thrombocythemia, the body produces too many platelet cells. The signs and symptoms vary from person to person, with up to two-thirds of patients not having any symptoms when the platelet cell count first increases. Signs and symptoms may include significant increased production of megakaryocyte (a cell in the bone marrow that is responsible for making platelets), enlargement of the spleen (splenomegaly), and bleeding and/or clotting episodes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Essential Thrombocythemia" returned 315 free, full-text research articles on human participants. First 3 results:

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
 

Author(s): Gabriela M Baerlocher, Bart Burington, David S Snyder

Journal: N. Engl. J. Med.. 2015 Dec;373(26):2580.

 

Last Updated: 24 Dec 2015

Go To URL
First successful pregnancy outcome after intrauterine insemination in a woman with primary infertility and essential thrombocythemia treated with interferon-alpha and aspirin.
 

Author(s): Danijela Leković, Mirjana Gotić, Aleksandar Ljubić

Journal: Srp Arh Celok Lek. ;143(3-4):210-3.

 

The management of pregnancy in young women with essential thrombocythemia is complex and may present a difficult problem. An adverse pregnancy outcome due to thrombosis or bleeding is a common complication. in addition, little is known about fertility in these women prior to the disease.

Last Updated: 27 May 2015

Go To URL
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
 

Author(s): Carla Al Assaf, Florence Van Obbergh, Johan Billiet, Els Lierman, Timothy Devos, Carlos Graux, Anne-Sophie Hervent, Jan Emmerechts, Thomas Tousseyn, Pascale De Paepe, Petros Papadopoulos, Lucienne Michaux, Peter Vandenberghe

Journal: Haematologica. 2015 Jul;100(7):893-7.

 

The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mutations are mutually exclusive in essential thrombocythemia and support a novel molecular categorization of essential thrombocythemia. CALR mutations account for approximately 30% of ...

Last Updated: 1 Jul 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Essential Thrombocythemia" returned 14 free, full-text review articles on human participants. First 3 results:

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
 

Author(s): Ayalew Tefferi, Tiziano Barbui

Journal: Am. J. Hematol.. 2015 Feb;90(2):162-73.

 

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis. Other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk ...

Last Updated: 23 Jan 2015

Go To URL
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.
 

Author(s): A Tefferi, T Barbui

Journal: Leukemia. 2013 Aug;27(8):1617-20.

 

The World Health Organization (WHO) classification system has recently strengthened the diagnostic criteria for essential thrombocythemia (ET) by lowering the threshold platelet count, underscoring its morphological distinction from early/prefibrotic myelofibrosis (MF) and incorporating ...

Last Updated: 7 Aug 2013

Go To URL
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
 

Author(s): Ayalew Tefferi

Journal: Am. J. Hematol.. 2012 Mar;87(3):285-93.

 

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms primarily characterized by erythrocytosis and thrombocytosis, respectively. Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, ...

Last Updated: 14 Feb 2012

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
 

Status: Not yet recruiting

Condition Summary: MPN; Essential Thrombocythemia

 

Last Updated: 19 Nov 2015

Go to URL
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
 

Status: Recruiting

Condition Summary: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia

 

Last Updated: 4 Jun 2015

Go to URL
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
 

Status: Recruiting

Condition Summary: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia

 

Last Updated: 4 Jun 2015

Go to URL